Age |
≤ 50 |
50 (49) |
> 50 |
52 (51) |
Histopathological Subtypes of Breast Cancer |
Invasive Ductal Carcinoma (IDC) |
92 (90.2) |
Invasive Lobular Carcinoma (ILC) |
6 (5.9) |
Mixed Carcinoma (IDC + ILC) |
4 (3.9) |
Nottingham Histological Grade |
I |
6 (5.8) |
II |
31 (30.4) |
III |
65 (63.8) |
Tumor Stage (pT) |
pT1 |
9 (8.8) |
pT2 |
73 (71.6) |
pT3 |
13 (12.7) |
pT4 |
7 (6.9) |
Lymph Node Involvement (pN) |
pN0 |
29 (28.4) |
pN1 |
31 (30.4) |
pN2 |
19 (18.6) |
pN3 |
15 (14.7) |
Unknown |
8 (7.9) |
Estrogen Receptor (ER) Status |
ER+ |
79 (77.5) |
ER- |
20 (19.6) |
Unknown |
3 (2.9) |
Progesterone Receptor (PR) Status |
PR+ |
66 (64.7) |
PR− |
33 (32.4) |
Unknown |
3 (2.9) |
HER2 Status |
Positive (3+) |
8 (7.9) |
Equivocal (2+) |
22 (21.6) |
Negative (0–1+) |
69 (67.6) |
Unknown |
3 (2.9) |
Ki-67 Proliferative Index (PI) |
Low (< 10%) PI |
16 (15.7) |
Intermediate (10–20%) PI |
12 (11.8) |
High (> 20%) PI |
25 (24.5) |
Unknown |
49 (48) |
HPV Expression |
Invasive ductal carcinoma (IDC) |
61 (59.8) |
Invasive lobular carcinoma (ILC) |
3 (2.9) |
Mixed carcinoma (IDC + ILC) |
1 (0.9) |
Invasive micropapillary carcinoma |
1 (0.9) |
EBV Expression |
Invasive ductal carcinoma (IDC) |
33 (32.4) |
Invasive lobular carcinoma (ILC) |
5 (4.9) |
Mixed carcinoma (IDC + ILC) |
2 (1.9) |
Invasive micropapillary carcinoma |
1 (0.9) |